nach oben

Journal of Inherited Metabolic Disease

Erschienen in:

01.05.2015 | Glycogenoses

Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes

verfasst von: Janice Y. Chou, Hyun Sik Jun, Brian C. Mansfield

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Disorders of the glucose-6-phosphatase (G6Pase)/glucose-6-phosphate transporter (G6PT) complexes consist of three subtypes: glycogen storage disease type Ia (GSD-Ia), deficient in the liver/kidney/intestine-restricted G6Pase-α (or G6PC); GSD-Ib, deficient in a ubiquitously expressed G6PT (or SLC37A4); and G6Pase-β deficiency or severe congenital neutropenia syndrome type 4 (SCN4), deficient in the ubiquitously expressed G6Pase-β (or G6PC3). G6Pase-α and G6Pase-β are glucose-6-phosphate (G6P) hydrolases with active sites lying inside the endoplasmic reticulum (ER) lumen and as such are dependent upon the G6PT to translocate G6P from the cytoplasm into the lumen. The tissue expression profiles of the G6Pase enzymes dictate the disease's phenotype. A functional G6Pase-α/G6PT complex maintains interprandial glucose homeostasis, while a functional G6Pase-β/G6PT complex maintains neutrophil/macrophage energy homeostasis and functionality. G6Pase-β deficiency is not a glycogen storage disease but biochemically it is a GSD-I related syndrome (GSD-Irs). GSD-Ia and GSD-Ib patients manifest a common metabolic phenotype of impaired blood glucose homeostasis not shared by GSD-Irs. GSD-Ib and GSD-Irs patients manifest a common myeloid phenotype of neutropenia and neutrophil/macrophage dysfunction not shared by GSD-Ia. While a disruption of the activity of the G6Pase-α/G6PT complex readily explains why GSD-Ia and GSD-Ib patients exhibit impaired glucose homeostasis, the basis for neutropenia and myeloid dysfunction in GSD-Ib and GSD-Irs are only now starting to be understood. Animal models of all three disorders are now available and are being exploited to both delineate the disease more precisely and develop new treatment approaches, including gene therapy.

Annabi B, Hiraiwa H, Mansfield BC et al (1998) The gene for glycogen-storage disease type 1b maps to chromosome 11q23. Am J Hum Genet 62(2):400–405PubMedCentralPubMedCrossRef

Banka S, Newman WG (2013) A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations. Orphanet J Rare Dis 8:84PubMedCentralPubMedCrossRef

Boers SJ, Visser G, Smit PG, Fuchs SA (2014) Liver transplantation in glycogen storage disease type I. Orphanet J Rare Dis 9(1):47PubMedCentralPubMedCrossRef

Boztug K, Appaswamy G, Ashikov A et al (2009) A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med 360(1):32–43PubMedCentralPubMedCrossRef

Chen LY, Shieh JJ, Lin B et al (2003) Impaired glucose homeostasis, neutrophil trafficking and function in mice lacking the glucose-6-phosphate transporter. Hum Mol Genet 12(19):2547–2558PubMedCrossRef

Chen SY, Pan CJ, Nandigama K, Mansfield BC, Ambudkar SV, Chou JY (2008) The glucose-6-phosphate transporter is a phosphate-linked antiporter deficient in glycogen storage disease type Ib and Ic. FASEB J 22(7):2206–2213PubMedCrossRef

Cheung YY, Kim SY, Yiu WH et al (2007) Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatase-beta. J Clin Invest 117(3):784–793PubMedCentralPubMedCrossRef

Chou JY, Mansfield BC (2008) Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat 29(7):921–930PubMedCentralPubMedCrossRef

Chou JY, Mansfield BC (2011) Recombinant AAV-directed gene therapy for type I glycogen storage diseases. Expert Opin Biol Ther 11(8):1011–1024PubMedCentralPubMedCrossRef

Chou JY, Mansfield BC (2014) The SLC37 family of sugar-phosphate/phosphate exchangers. Curr Top Membr 73:357–382PubMedCentralPubMedCrossRef

Chou JY, Matern D, Mansfield BC, Chen YT (2002) Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2(2):121–143PubMedCrossRef

Chou JY, Jun HS, Mansfield BC (2010) Glycogen storage disease type I and G6Pase-beta deficiency: etiology and therapy. Nat Rev Endocrinol 6(12):676–688PubMedCentralPubMedCrossRef

Ekstein J, Rubin BY, Anderson SL et al (2004) Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet A 129A(2):162–164PubMedCrossRef

Franco LM, Krishnamurthy V, Bali D et al (2005) Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 28(2):153–162PubMedCrossRef

Gerin I, Veiga-da-Cunha M, Achouri Y, Collet JF, Van Schaftingen E (1997) Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type Ib. FEBS Lett 419(2–3):235–238PubMedCrossRef

Ghosh A, Shieh JJ, Pan CJ, Sun MS, Chou JY (2002) The catalytic center of glucose-6-phosphatase. HIS176 is the nucleophile forming the phosphohistidine-enzyme intermediate during catalysis. J Biol Chem 277(36):32837–32842PubMedCrossRef

Ghosh A, Shieh JJ, Pan CJ, Chou JY (2004) Histidine 167 is the phosphate acceptor in glucose-6-phosphatase-beta forming a phosphohistidine enzyme intermediate during catalysis. J Biol Chem 279(13):12479–12483PubMedCrossRef

Hiraiwa H, Pan CJ, Lin B, Moses SW, Chou JY (1999) Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 274(9):5532–5536PubMedCrossRef

Jun HS, Lee YM, Cheung YY et al (2010) Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose-6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome. Blood 116(15):2783–2792PubMedCentralPubMedCrossRef

Jun HS, Lee YM, Song KD, Mansfield BC, Chou JY (2011) G-CSF improves murine G6PC3-deficient neutrophil function by modulating apoptosis and energy homeostasis. Blood 117(14):3881–3892PubMedCentralPubMedCrossRef

Jun HS, Cheung YY, Lee YM, Mansfield BC, Chou JY (2012) Glucose-6-phosphatase-beta, implicated in a congenital neutropenia syndrome, is essential for macrophage energy homeostasis and functionality. Blood 119(17):4047–4055PubMedCentralPubMedCrossRef

Jun HS, Weinstein DA, Lee YM, Mansfield BC, Chou JY (2014) Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. Blood in press

Kilpatrick L, Garty BZ, Lundquist KF et al (1990) Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest 86(1):196–202PubMedCentralPubMedCrossRef

Kim SY, Jun HS, Mead PA, Mansfield BC, Chou JY (2008) Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib. Blood 111(12):5704–5711PubMedCentralPubMedCrossRef

Koeberl DD, Pinto C, Sun B et al. (2008) AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther 16(4):665–672

Kishnani PS, Faulkner E, VanCamp S et al (2001) Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia). Vet Pathol 38(1):83–91PubMedCrossRef

Koeberl DD, Kishnani PS, Bali D, Chen YT (2009) Emerging therapies for glycogen storage disease type I. Trends Endocrinol Metab 20:252–258PubMedCrossRef

Kuijpers TW, Maianski NA, Tool AT et al (2003) Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b). Blood 101(12):5021–5024PubMedCrossRef

Lee YM, Jun HS, Pan CJ et al (2012) Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy. Hepatology 56(5):1719–1729PubMedCentralPubMedCrossRef

Lee YM, Pan CJ, Koeberl DD, Mansfield BC, Chou JY (2013) The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia. Mol Genet Metab 110(3):275–280PubMedCentralPubMedCrossRef

Lei KJ, Shelly LL, Pan CJ, Sidbury JB, Chou JY (1993) Mutations in the glucose-6-phosphatase gene that cause glycogen-storage-disease type-1a. Science 262(5133):580–583PubMedCrossRef

Lei KJ, Chen H, Pan CJ et al (1996) Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type-1a mouse. Nat Genet 13(2):203–209PubMedCrossRef

Lin B, Pan CJ, Chou JY (2000) Human variant glucose-6-phosphate transporter is active in microsomal transport. Hum Genet 107(5):526–529PubMedCrossRef

Martin CC, Oeser JK, Svitek CA, Hunter SI, Hutton JC, O'Brien RM (2002) Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein. J Mol Endocrinol 29(2):205–222PubMedCrossRef

Matern D, Seydewitz HH, Bali D, Lang C, Chen YT (2002) Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 161(Suppl 1):S10–S19PubMedCrossRef

McCawley LJ, Korchak HM, Cutilli JR et al (1993) Interferon-gamma corrects the respiratory burst defect in vitro in monocyte-derived macrophages from glycogen storage disease type 1b patients. Pediatr Res 34(3):265–269PubMedCrossRef

McDermott DH, De Ravin SS, Jun HS et al (2010) Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood 116(15):2793–2802PubMedCentralPubMedCrossRef

Michelfelder S, Trepel M (2009) Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 67:29–60PubMedCrossRef

Mutel E, Abdul-Wahed A, Ramamonjisoa N et al (2011) Targeted deletion of liver glucose-6 phosphatase mimics glycogen storage disease type 1a including development of multiple adenomas. J Hepatol 54(3):529–537PubMedCrossRef

Pan CJ, Lei KJ, Annabi B, Hemrika W, Chou JY (1998) Transmembrane topology of glucose-6-phosphatase. J Biol Chem 273(11):6144–6148PubMedCrossRef

Pan CJ, Lin B, Chou JY (1999) Transmembrane topology of human glucose 6-phosphate transporter. J Biol Chem 274(20):13865–13869PubMedCrossRef

Peng WT, Pan CJ, Lee EJ, Westphal H, Chou JY (2009) Generation of mice with a conditional allele for G6pc. Genesis 47(9):590–594PubMedCentralPubMedCrossRef

Pierre G, Chakupurakal G, McKiernan P et al (2008) Bone marrow transplantation in glycogen storage disease type 1b. J Pediatr 152(2):286–288PubMedCrossRef

Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002) Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161(Suppl 1):S20–S34PubMedCrossRef

Rocca CJ, Ur SN, Harrison F, Cherqui S (2014) rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study. Gene Ther 21(6):618–628PubMedCentralPubMedCrossRef

Shah KK, O'Dell SD (2013) Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis. J Hum Nutr Diet 26(4):329–339PubMedCrossRef

Shieh JJ, Terzioglu M, Hiraiwa H et al (2002) The molecular basis of glycogen storage disease type 1a: structure and function analysis of mutations in glucose-6-phosphatase. J Biol Chem 277(7):5047–5053PubMedCrossRef

Shieh JJ, Pan CJ, Mansfield BC, Chou JY (2003) A glucose-6-phosphate hydrolase, widely expressed outside the liver, can explain age-dependent resolution of hypoglycemia in glycogen storage disease type Ia. J Biol Chem 278(47):47098–47103PubMedCrossRef

Visser G, Rake JP, Labrune P et al (2002) Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161(Suppl 1):S83–S87PubMedCrossRef

Weinstein DA, Correia CE, Conlon T et al (2010) Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum Gene Ther 21(7):903–910PubMedCentralPubMedCrossRef

Yiu WH, Lee YM, Peng WT et al (2010) Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol Ther 18(6):1076–1084

Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16(6):1073–1080PubMedCrossRef

Titel: Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes
verfasst von: Janice Y. Chou
Hyun Sik Jun
Brian C. Mansfield
Publikationsdatum: 01.05.2015
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 3/2015
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-014-9772-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease

Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions

Next generation mitochondrial disease: change in diagnostics with eyes on therapy

Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children

Christian Körner